Perspectives from the ICU

Personal Experiences with Continuous Renal Replacement Therapy

Melissa discusses CRRT use on patient with life-threatening arrythmia

"I just remember he was suffering from a life-threatening arrhythmia, attributed to the potassium levels. And he was too unstable for normal dialysis. Because we had that option (CRRT), we were able to decrease his serum potassium rapidly, without worsening his hypotension, without worsening his other organ failure, and stop the arrhythmogenic situation."

Melissa Bastin-Thompson, PharmD, BCPS

Becca talks about using CRRT on a cardiac-arrest patient

"We had a cardiac arrest patient who was still not talkative after hypothermic protocol. We did CRRT on him just to see if it would help. I came in on Monday and he’s talking and making jokes. And I mean it was just amazing…"

Becca Bauer, RN

Dr. Aycinena discusses his experience with CRRT for patient with mantle cell lymphoma

"The most dramatic cases that I have experienced both had mantle cell lymphoma. I remember one patient came in loaded on pressors…we thought was going to pass away and he did a one-eighty, and within 24 hours was off any pressors. I think the (CRRT) combined with the chemotherapy really made a difference."

Juan Carlos Aycinena, MD

Jillian discusses use of CRRT on patient with HUS

"We had a young girl come in that ended up having HUS. And she was literally on her deathbed. We hooked her up (to CRRT) and three days later she was extubated, a week and a half later she was out of the ICU, and two weeks later back at school."

Jillian Kouns, RN

Clinical Q&A

Clinician Q&A

Do you find the PRISMAFLEX System easy to use when delivering CRRT?

View resource
Clinician Q&A

How does Baxter’s CRRT Program help provide value to your hospital?

View resource
Clinician Q&A

How has Baxter’s Complete Support made a difference for your CRRT program?

View resource
Clinician Q&A

What are the keys to success with implementing a CRRT program?

View resource
Clinician Q&A

What factors potentially affect patient safety when delivering CRRT?

View resource
Clinician Q&A

How do you avoid treatment downtime?

View resource
Clinician Q&A

How does the flexibility of the PRISMAFLEX System help you on a daily basis?

View resource

Indications and Important Risk Information

The PRISMAFLEX and PRISMAX Systems are intended for:
Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload.

Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where fluid removal of plasma components is indicated.

Rx Only. For the safe and proper use of the products mentioned herein refer to the appropriate Instructions for Use or Operator's Manual.


PHOXILLUM and PRISMASOL Renal Replacement Solution Indications and Important Risk Information

Indications

PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances

Important Risk Information

PHOXILLUM and PRISMASOL replacement solutions are contraindicated in patients with known hypersensitivities to these products.

PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure.

PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis. 

PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. 

The following adverse reactions have been identified during post-approval use with these or other similar products and therefore may occur with use of PHOXILLUM or PRISMASOL: Metabolic acidosis, hypotension, acid-based disorders, electrolyte imbalances including calcium ionized increased, hyperphosphatemia, hypophosphatemia, fluid imbalance.

For more information, please see PHOXILLUM and PRISMASOL Solutions full Prescribing Information  or visit baxterpi.com.


PRISMASATE Intended Use

PRISMASATE Dialysate Formula is intended for treatment of acute kidney disease (renal failure) using Continuous Renal Replacement Therapies, such as continuous hemodialysis and hemodiafiltration aimed at normalizing the composition of the blood. It may also be used in case of drug poisoning with dialyzable or filterable substances. 


MARS Indications

MARS is indicated for the treatment of drug overdose and poisonings. The only requirement is that the drug or chemical be dialyzable (in unbound form) and bound by charcoal and/or ion exchange resins.

MARS is not indicated for the treatment of chronic liver disease conditions or as a bridge to liver transplant. Safety and efficacy has not been demonstrated for those indications in controlled, randomized clinical trials. The effectiveness of the MARS device in patients that are sedated could not be established in clinical studies and therefore cannot be predicted in sedated patients.